SUPERNUS PHARMACEUTICALS, INC.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $SUPN in the last 30 days.
See all $SUPN insider activity →Supernus Pharmaceuticals terminated its credit line with UBS on October 20, 2026, ahead of its planned combination with Indivior. No borrowings or penalties were involved, and UBS released its security interests. The move is part of preparations for the combined company's new credit facility.
SUPERNUS PHARMACEUTICALS, INC. (SUPN) filed an SEC Form 8-K — Termination of a Material Definitive Agreement. Item 1.02 Termination of a Material Definitive Agreement. On October 20, 2026, Supernus Pharmaceuticals, Inc. (the “Company”) terminated the UBS Credit Line Agreement, dated as of February 8, 2023 (the “UBS Credit Line”), between the Company and UBS Bank USA (the “Bank”), which e
SUPERNUS PHARMACEUTICALS, INC. (SUPN) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Supernus Announces Orphan Drug Exclusivity for ONAPGO™ (apomorphine HCl) Orphan-drug exclusivity provides seven years of market exclusivity for ONAPGO Additionally, the Company submitted an sNDA to the FDA for a second supplier for ONAPGO, with potential approval by
Over the past 7 days, AlphAI's AI scored 6 news stories mentioning SUPN (SUPERNUS PHARMACEUTICALS, INC.). Coverage has skewed bullish: 3 bullish, 3 neutral, and 0 bearish.
Recent SUPN coverage spans corporate actions, mergers & acquisitions and regulation.
The termination removes an unused financing source but signals preparation for the upcoming merger, likely having limited immediate price effect.
Termination removes an unused credit facility and signals confidence in merger financing, likely supporting the stock.
Orphan exclusivity secures market protection, likely supporting SUPN's revenue outlook and pricing power.
The exclusivity protects ONAPGO from competition, supporting revenue stability and potential price appreciation.
The announcement sets a date for the earnings release, likely keeping the stock neutral until the actual results.
AlphAI scores every news story that mentions SUPN with an AI model for sentiment and relevance, and aggregates insider trades from SUPERNUS PHARMACEUTICALS, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Supernus Pharmaceuticals terminated its credit line with UBS on October 20, 2026, ahead of its planned combination with Indivior. No borrowings or penalties were involved, and UBS released its security interests. The move is part of preparations for the combined company's new credit facility.
1 min readSUPERNUS PHARMACEUTICALS, INC. (SUPN) filed an SEC Form 8-K — Termination of a Material Definitive Agreement. Item 1.02 Termination of a Material Definitive Agreement. On October 20, 2026, Supernus Pharmaceuticals, Inc. (the “Company”) terminated the UBS Credit Line Agreement, dated as of February 8, 2023 (the “UBS Credit Line”), between the Company and UBS Bank USA (the “Bank”), which e
1 min readSUPERNUS PHARMACEUTICALS, INC. (SUPN) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Supernus Announces Orphan Drug Exclusivity for ONAPGO™ (apomorphine HCl) Orphan-drug exclusivity provides seven years of market exclusivity for ONAPGO Additionally, the Company submitted an sNDA to the FDA for a second supplier for ONAPGO, with potential approval by
1 min readSupernus (SUPN) announced FDA orphan-drug exclusivity for ONAPGO, a Parkinson's treatment, ensuring seven years of market exclusivity starting February 2025. The company also submitted an sNDA for a second supplier, with potential approval by mid-2027, addressing supply issues and reinforcing its commitment to Parkinson's therapies.
2 min readSUPERNUS PHARMACEUTICALS, INC. (SUPN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Supernus Pharmaceuticals to Announce Third Quarter 2026 Financial Results and Host Conference Call on October 29, 2026 ROCKVILLE, Md., October 19, 2026 – Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializ
1 min readSUPERNUS PHARMACEUTICALS, INC. (SUPN) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07 Submission of Matters to a Vote of Security Holders. On October 15, 2026 Supernus Pharmaceuticals, Inc. (the “Company”) held a special meeting of its stockholders (the “Special Meeting”). The definitive proxy statement pertaining to the Special Meeting was previously fi
4 min readCollegium Pharmaceutical (COLL) reported $199.9M revenue, up 6.3% YoY, missing expectations. Its stock fell 38.3%. Eli Lilly (LLY) reported $22.97B revenue, up 47.7%, beating expectations. Its stock rose 5.9%. Supernus Pharmaceuticals (SUPN) reported $211.3M revenue, up 27.7%, exceeding expectations. Its stock fell 4%.
6 min readIndivior and Supernus disclosed supplemental proxy materials ahead of their merger. Indivior will be renamed Supernus post-merger. Cantor Fitzgerald's updated valuation ranges for Supernus are $50.55–$59.50 per share, and for Indivior, $24.20–$43.90 after adjustments. The supplement addresses stockholder concerns and denies wrongdoing.
1 min readIndivior Pharmaceuticals (INDV) filed an S-4 for an all-stock merger with Supernus Pharmaceuticals (SUPN). Each Supernus share will convert to 1.5401 Indivior shares. Indivior plans a $1B special dividend, contingent on merger completion, with a $650M loan to fund it. Post-merger, Indivior will rename to Supernus and trade under SUPN. The deal is expected to close in Q4 2026, subject to approvals.
3 min readSupernus Pharmaceuticals (SUPN) announced a merger with Indivior (INDV) and reported Q2 earnings. Revenue rose 32% to $219M, but net loss was $58M. The all-stock deal, pending approval, is expected to close Q4 2023. Stock closed 3% higher.
3 min read
